The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC).
 
Gini Fleming
Research Funding - Abbvie (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celldex (Inst); Compugen (Inst); Compugen (Inst); Corcept Therapeutics (Inst); Duality Biologics (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Merck (Inst); Molecular Templates (Inst); P{fizer (Inst); Pheast Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Systimmune (Inst)
 
Katherine Kurnit
Honoraria - OncLive/MJH Life Sciences
Travel, Accommodations, Expenses - GOG Partners
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); Curio Science (Inst); CytomX Therapeutics (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Pamela Munster
Leadership - Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; Olema Oncology; OnKure
Honoraria - Caris Life Sciences; GlaxoSmithKline; Merck
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; Catalent; Incendia Pharmaceuticals AB; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Cyteir; Deciphera (Inst); Frontier Medicines; Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); IgM Biosciences (Inst); InventisBio (Inst); Merck (Inst); Novartis (Inst); Nurix; ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Seagen (Inst); Skorpion (Inst); Tempest Therapeutics (Inst); Vividion Therapeutics; Xencor (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
Other Relationship - ABIM Subspecialty Board; ANCO; NIH/NCI
 
Raymond Wadlow
Honoraria - Astellas Pharma; BeOne Medicines; Incyte; Pfizer
Consulting or Advisory Role - Ipsen; Johnson & Johnson (I)
 
Shigehiro Koganemaru
Research Funding - Abbvie (Inst); Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi-Sankyo (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Chiyoe Kitagawa
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; MSD; Ono Yakuhin; Taiho Pharmaceutical
Research Funding - Abbvie; ALX Oncology; Daiichi Sankyo/Astra Zeneca; MSD; Ono Yakuhin; Sanofi
 
Takako Nakajima
Honoraria - Bristol-Myers Squibb Japan; Celltrion Healthcare Japan K.K.; Chugai Pharma; Daiichi Sankyo/UCB Japan; IQVIA SolutionsJapan K.K.; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - FIMECS, Inc.; Shinobi Therapeutics; Thyas Co. Ltd (Inst)
Research Funding - Abbvie (Inst); BTB Therapeutics; Chugai Pharma (Inst); Immunohelix; IQVIA Solutions Japan K.K.; KBBM (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); Parexel international inc; Taiho Pharmaceutical (Inst); Taisho Pharmaceutical Holdings (Inst); Takeda (Inst); Thermo Fisher Scientific; Toregem BioPharma Co., Ltd. (Inst); Zymeworks (Inst)
 
Yuta Maruki
No Relationships to Disclose
 
Ruth Perets
Employment - Rambam Health Care Campus
Honoraria - AstraZeneca; GlaxoSmithKline
Consulting or Advisory Role - 1E Therapeutics; Biond Biologics; GlaxoSmithKline; MSD; NeoPharm; Nevia Bio; Roche/Genentech; Simplivia
Research Funding - 1E Therapeutics (Inst); Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Gilead Sciences (Inst)
 
Akosua Badu-Nkansah
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Martha Blaney
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Manal Mehibel
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Pin Li
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Marjilla Seddiq
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Anna Shurshalina
Employment - Abbvie
Leadership - Abbvie
Stock and Other Ownership Interests - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Omar Al Yacoub
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Research Funding - Abbvie
Travel, Accommodations, Expenses - Abbvie
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Michael Burns
Employment - Abbvie; Pfizer
Stock and Other Ownership Interests - Abbvie; Pfizer
Patents, Royalties, Other Intellectual Property - Pending Patent Abbvie
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Janssen; Kyowa Kirin International; Lilly Japan; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; GlaxoSmithKline; ImmuniT Research Inc.; Kyowa Kirin; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; United Immunity
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kyowa Kirin (Inst); Lilly (Inst); Loxo/Lilly (Inst); Medpace (Inst); Merck KGaA (Inst); Moderna Therapeutics (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst); Takara Bio (Inst); Takeda (Inst)